Immunovant, Inc. (IMVT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
| Previous Close | 28.22 |
| Open | 28.59 |
| Bid | 28.70 x 300 |
| Ask | 28.79 x 300 |
| Day's Range | 27.94 - 28.89 |
| 52 Week Range | 15.90 - 45.58 |
| Volume | |
| Avg. Volume | 1,155,206 |
| Market Cap | 4.176B |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
- Zacks
What Makes Immunovant (IMVT) a New Buy Stock
Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Investor's Business Daily
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.
© 2024 Yahoo. All rights reserved.